(lncRNAs) range from ≈200 nt to >100 kb in length, excluding infrastructural or regulatory RNAs (tRNAs, miRs, siRNAs, etc.). Estimates of the number of lncRNAs from transcriptional surveys in mammals suggest that they may outnumber proteincoding genes, but only to a minute fraction of lncRNAs biological functions have been assigned.
Noncoding transcripts (miRs and lncRNAs) are also increasingly investigated as novel diagnostic and prognostic disease markers. [13] [14] [15] [16] The following study addressed a human cardiac disease caused by a common single-stranded RNA enterovirus (CVB3) and searched for factors determining the highly variable course of the disease. This virus usually causes transient enteritic disease only, but cardiac infection in a fraction of infected individuals is a frequent cause of terminal heart failure affecting children or adolescents even more frequently than adults. Some patients with CVB3 cardiomyopathy may spontaneously eliminate the virus and recover, whereas those with virus persistence deteriorate and progress to heart failure. TO date, no predictive molecular marker to distinguish virus-eliminating patients (CVB3-ELIM) from those prone to persistence (CVB3-PERS) is available but would provide a rational basis for immediate initiation of antiviral interferon-β. This treatment is efficient, but not without side effects, and should be started as early as possible to prevent irreversible damage to the heart. [17] [18] [19] By transcriptome mapping of protein-coding genes and miRs in endomyocardial biopsies (EMBs) of CVB3 Figure 1 . Test and validation cohorts of patients. Test cohorts of patients with CVB3 cardiomyopathy with either spontaneous elimination (CVB3-ELIM) or persistence of their cardiotropic virus (CVB3-PERS) were selected for endomyocardial biopsy (EMB)-based transcriptome mapping (Methods in the Data Supplement). A, These 2 test groups were not significantly different on clinical symptoms, hemodynamic, or echocardiographic parameters at their initial presentation. At this time point, endomyocardial biopsies defined as baseline EMBs were taken not only for the standard diagnostics but also for miR profiling. Only these baseline miR values are reported in Figures 2 and 3 . All evaluations of predictive potential of miRs ( Figure 6 ; Table) also refer to the baseline miR data. B, When compared with their initial findings (left, red bar), CVB3-ELIM patients had significantly improved symptoms and left ventricular ejection fraction (LVEF) after 6 months (yellow bar), the time point of follow-up EMBs, and normalized hemodynamics after 1 year (green bar). In contrast, the CVB3-PERS patients with CVB3 persistence (right) had no improvement of symptoms or LVEF after 6 months (yellow bar) and subcutaneous interferon (IFN)-β therapy was initiated at this time. IFN-β led to clinical and function improvement, still LVEF remained significantly impaired at the end of the 6 months treatment period (red bar). This improvement, but lack of normalization, emphasizes the need to start treatment as early as possible to prevent irreversible cardiac injury and adverse long-term prognosis because of cardiac persistent CVB3. C, On the basis of baseline miR expression data from the test cohorts (screening phase), 16 significantly deregulated miRs ( Figure 2 ) were further investigated in the validation cohorts of CVB3-ELIM (n=30) vs CVB3-PERS (n=10) patients who also showed no significant differences at their initial presentation. In the validation cohorts, all miR data ( Figure 3 ) are also derived from their baseline EMBs. A, A adenoviral (AdV) cardiomyopathy patients with severely impaired LVEF, and healthy controls (CONT), who underwent miR profiling during the initial screening phase only and were not further followed up during the validation phase. CONT initially presented with suspected cardiac origin of their complaints, but had exclusion of cardiac pathology at the end of diagnostic workup. Numeric values in A and C are means±SD. *P<0.01. m/w indicates males/females. cardiomyopathy patients at their initial presentation, we identified a predictive miR expression pattern associated with defective virus elimination and clinical deterioration. A clinical aspect of this study is the application of cardiac miR profiling to identify patients requiring supportive antiviral, so that irreversible cardiac damage can be minimized. A basic science aspect is the observation that profiling of protein-coding genes failed to identify a predictive marker, whereas the individual capacity for virus elimination was determined or reflected by noncoding genomic elements (miRs).
Methods

Study Patients
The clinical and EMB-based molecular virological and immunohistochemical data of all study patients, as summarized in Figure 1 , were obtained using methods published previously. The diagnosis of CVB3 cardiomyopathy was made as described [17] [18] [19] and encompassed exclusion of coronary, hypertensive, valvular, restrictive, or constrictive heart disease. In the CVB3 cardiomyopathy patients reported here, none of the following comorbities was present: lung diseases (chronic obstructive pulmonary disease, asthma bronchiale, pulmonary hypertension, pulmonary fibrosis, or emphysema), endocrine disorders (diabetes mellitus, thyroid dysfunction, and adrenal dysfunction; further information is available in the Data Supplement).
The study design was as follows: at the first presentation of the patients, without knowledge of their subsequent clinical and virological course, EMBs defined as baseline EMBs were taken not only for the standard diagnostics (histology, immunohistology, and molecular virology) but also for microRNA profiling. From these baseline EMBs, we have determined myocardial miR profiles, and only these baseline miR values are reported in Figures 2 to 4 and in Table I Table) refer to the baseline miRs only. No additional miR profiling was conducted after the first presentation and baseline examination of patients.
Figure 2.
Differential cardiac miR expression patterns in human viral cardiomyopathies. In the screening phase, endomyocardial biopsies (EMBs) from the 4 test patient cohorts underwent miR expression profiling addressing 756 human miRs. Primary comparison was CVB3-ELIM vs Cox-PERS. In addition, adenovirus (AdV) cardiomyopathy patients and controls without cardiac pathology were analyzed by the same assays. If the 4 test cohorts are jointly considered, the miRs deregulated in CVB3-ELIM vs CVB3-PERS may be assigned to different response types as indicated by red and blue color, respectively. A, Eight miRs displaying a type I response characterized by strong induction in only one of the test cohorts (CVB3-PERS), whereas in all other groups they are undetectable or low. These miRs 135b-5p, 155-5p, 190a-5p, 422a, 489-3p, 590-5p, 601, and 1290 significantly (**P<0.01) distinguish CVB3-PERS not only from CVB3-ELIM but also from CONT and AdV group. B, Eight miRs with opposite behavior on CVB3-PERS vs CVB3-ELIM. These type II response miRs include let-7a-5p and let-7f-5p, miRs 296-5p, 339-5p, 365a-3p, 532-5p, 660-5p, and 520e. They were undetectable in CVB3-PERS and thus distinguish them from CVB3-ELIM. **P<0.01, the 3 horizontal lines on each plot denote mean±SD.
The distinction between CVB3-PERS and CVB3-ELIM patient cohorts was made based on follow-up EMBs from each patient 6 months after his/her first presentation. These follow-up EMBs included histology, immunohistology, and molecular virology again, but not again any miR studies. Virological status at this time served to classify patients into CVB3-ELIM or CVB3-PERS.
Cardiac mRNA and miR Expression Studies
Protein-Encoding Transcripts mRNAs were evaluated by Affymetrix U133 plus 2.0 microarray analysis of total RNA extracted from human EMBs using mirVana miRNA Isolation Kit (Applied Biosystems) according to manufacturer instructions. cDNA target synthesis and hybridization to the arrays were conducted with 2 rounds of amplification: for the first cycle of cDNA synthesis, 10 to 40 ng of total RNA was used, reverse transcription (RT) and second strand synthesis was performed using Message Amp II amplification kit (Ambion). The first round in vitro transcription reaction must contain only unmodified nucleotides, so it was performed using in vitro transcription mixture from Megascript T7 kit (Ambion). Obtained cRNA was then transcribed into cDNA using random primer and reverse transcriptase RTII (Invitrogen) and then the leaving part was degraded by RNAse H (Roche). After T7 oligo (dT) primer annealing, a second strand was synthesized. The product contained T7 promotor sequence for the second in vitro transcription reaction, conducted to generate biotinylated cRNA (Message Amp II Amplification Kit, Ambion). Labeled cRNA was cleaned up, fragmented, and added to a hybridization cocktail for hybridization to the U133 2.0 plus GeneChip expression array, also containing 50 pM control oligonucleotide B2, eukaryotic hybridization controls, according to manufacturer protocol (Hybridization Wash and Stain Kit, Affymetrix). Hybridization was at 45°C and 60 rpm for 16 hours, and scanning was on GeneChipScanner 3000 G7 system (Affymetrix).
microRNAs
We analyzed a total of 756 miRs. RT and preamplification (preamp) were performed using an Eppendorf Mastercycler and qunatitative polymerase chain reaction (PCR) reactions were performed on 7900HT Fast Real-Time PCR System (Applied Biosystems). Comprehensive coverage of Sanger miRBase v14 is enabled across a 2-card set of TaqMan Array MicroRNA Cards (cards A and B) for a total of 754 unique assays specific to human miRs. The Megaplex RT Primers are highly multiplexed RT primers designed to convert ≤381 miRs to cDNA before real-time analysis and required to run the TaqMan Array MicroRNA Cards. A total of 7.5 μL of RT reaction contained the following: 3.2 μL RNA, 0.8 μL 10X RT primer mix (pool A or pool B), 0.2 μL 100 mmol/L dNTPs, 1.5 μL 50 U/μL MultiScribe Reverse Transcriptase, 0.8 μL 10X RT buffer, 0.9 μL 25 mmol/L MgCl 2 and 0.1 μL 20 U/μL RNase inhibitor. The RT reaction was performed in the thermocycler under the following conditions: (16°C for 2 minutes, 42°C for 1 minute, and 50°C for 1 s) for 40 cycles and 85°C for 5 minutes.
Because of the limited amount of RNA available from EMBs, we used Megaplex PreAmp Primers for a preamp step before real-time analysis to improve sensitivity. During the preamp, PCR products are uniformly amplified from cDNA templates without introducing Figure 3 summarizes analogous data in the validation cohorts for 12 miRs with asymptotic significance P<0.05 by univariate analysis (Table) . A, Six type I and (B) 6 type II response miRs with specific P values for each miR. #Significance after Bonferroni correction. C, A summary heat map of miR deregulations in both the test and the validation cohorts. miRs upregulated in CVB3-PERS are encoded red, and those upregulated in CVB3-ELIM vs CVB3-PERS patients are encoded blue. a bias. Preamp reactions contained 2.5 μL of RT product, 12.5 μL 2X Taqman Preamp Master Mix, 2.5 μL 10X Megaplex PreAmp Primers (pool A or pool B), and 7.5 μL water. The preamplification reaction was performed in the thermocycler under the following conditions: 95°C for 10 minutes, 55°C for 2 minutes, 72°C for 2 minutes, and (95°C for 15 s, 60°C for 4 minutes) for 12 cycles and 99.9°C for 10 minutes. Then, the preamp product was diluted 4-fold by adding 75 μL of 0.1× TE pH 8.0. The real-time PCR reactions were performed using human TaqMan Array MicroRNA cards A and B according to manufacturer instructions. RT product was mixed with 2× TaqMan Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems) and loaded onto the TLDA (Taqman low density array block) containing the 384-plex PCR reaction mix. TLDAs were run on 7900HT Thermocycler (Applied Biosystems) using Sequence Detection Systems software version 2.2.
RT-PCR Analyses of Human Peripheral Blood Mononuclear Cells and Cultured Cells
Preparation and Stimulation of Human Mononuclear Cells
For blood samples of healthy donors, the study was reviewed and approved by the Institutional Ethics Committee and informed consent was obtained from the donors. Blood was collected using BD Vacutainer blood collection system for human or heparin-containing Eppendorf tubes for murine blood. Blood was diluted 1:1 with PBS and separated under sterile conditions by gradient centrifugation using Biocoll at 850 g for 20 minutes at RT without brake. The fraction of peripheral blood mononuclear cells (PBMCs) was collected, washed, diluted 1:1 with PBS, and centrifuged at 400g for 10 minutes at RT. Cells were allowed to rest for 2 hours in Iscove's Modified Dulbecco's medium supplemented with 1% L-glutamine, 10% human AB serum, and 1% each of penicillin/streptomycin at 37°C, 5% CO 2 , and then 1×10 7 cells were either left unstimulated or were stimulated with each 100 ng/mL PMA (phorbol 12-myristate 13-acetate), 100 μg/mL Ionomycin (Sigma), 100 ng/mL interleukin-10 (Sigma), 100 ng/mL lipopolysaccharide (Sigma), or 300 U/mL interferon-β (Bayer) for 4 hours. Afterward, the cells were washed twice with PBS and the pellet resuspended in 700 μL of QIAzol Lysis Reagent (Quiagen) for miR preparation and frozen at −80°C.
Human THP-1 Cell Culture and Anti-miR Antisense Oligonucleotide Treatment
THP-1 cells were cultured in RPMI 1640 supplemented with 10% FCS. 5×10 5 cells were seeded in 12-well culture plates and 24 hours later transfected with 50 nmol/L of locked nucleic acid (LNA) antisense oligonucleotide (ASO) plus 3 μL of RNAiMAX per well in OptiMEM medium. LNA-ASO against the target miR was compared with scrambled LNA-ASO as a control. All LNA-ASOs were obtained from Exiqon (Vedbaek, Denmark) and were tested endotoxin free. Forty eight hours after transfection, quantitative RT-PCR analyses were conducted as described below.
RNA Isolation, cDNA Transcription, and Quantitative RT-PCR Analyses
Total RNA and miRs were isolated from human cultured THP-1 cells or human PBMCs using miRNeasy Mini Kit (Qiagen). For gene expression analyses, isolated RNA was digested using RNase free peqGOLD DNase I (Peqlab) for 30 minutes to avoid DNA contamination. One to 1.5 μg of total RNA was reverse transcribed using High Capacity RNAto-cDNA kit (Life Technologies) and finally diluted to a concentration Figure  2 , for man and mouse, with sequence differences between species underlined italic (miR-155, 422a, and 489), and a note if no murine homologue to the human miR exists. Type I miRs that are induced in CVB3-PERS hearts are shown in red. of 25 ng/μL. Expression levels were determined by RT-PCR using master mix and the respective gene expression assay. All gene expression data were normalized to HPRT (hypoxanthin-guanin-phosphoribosyltransferase) mRNA levels as an endogenous control.
Bioinformatic Algorithms and miR Target Identification
For miR target prediction, we used the miR databases and target prediction tools miRBase (http://microrna.sanger.ac.uk/), TargetScan (http:// www.targetscan.org/index.html), and the Ingenuity System software tools. Predicted and experimentally observed targets for the cardiac deregulated miRs are shown in Tables II and III in the Data Supplement.
Statistical Analyses
Descriptive statistics include absolute and relative frequencies for categorial variables and mean and SD for quantitative measurements. Of 754 microRNA candidates in a learning sample of 13 subjects (7 CVB3-PERS and 6 CVB3-ELIM), 16 were identified as highly significantly (P≤0.01) associated with persistence, using the Mann-Whitney U test. These 16 mRNAs were analyzed in a validation sample of 40 patients (10 CVB3-PERS and 30 CVB3-ELIM). Diagnostic accuracy was evaluated by univariate receiver operating characteristic curve (ROC) analysis, and area under the curves with 95% confidence intervals are presented (Table) . In addition, a multivariate discriminant analysis model was fitted in the learning cohort and the resulting multivariate ROCs and area under the curves after transferring the equation into the validation sample are presented ( Figure 6 ). miR-190, let7f, miR-365-3p, miR-339-5p, miR-296-5p, and miR-520e had to be excluded from the fitted discriminant function because they did not meet the tolerance criteria. Statistical analyses have been performed using SPSS 21 and StatcaIC13. A value of P≤0.05 was considered statistically significant.
Data Analysis From Affymetrix U133 Plus 2.0 Microarrays
For data analysis, the Affymetrix cel-files were imported in the Partek Genomic Suite software (Partek Inc, St. Louis, MO) and normalized using the robust multiarray average algorithm.
Data Analysis From ABI TaqMan Array MiRNA Cards
miRNA expression was normalized to the RNA polymerase IIItranscribed U6 snRNA, which is a commonly used RNA for miRNA normalization, applying the formula: 2-ΔCt. Statistical analysis was performed using GraphPad Prism 4 software. The different groups were compared using the Student t test. A value of P<0.05 was considered statistically significant. Further details of all methods and associated references are available in the Data Supplement.
Results
Myocardial Expression Profiling of Protein-Coding Genes and miRs in CVB3 Cardiomyopathy
First, we conducted expression profiling of EMB samples taken at first presentation of test cohorts of CVB3 cardiomyopathy patients who either eliminated the virus spontaneously and recovered (CVB3-ELIM) or had persistent infection and progressive disease (CVB3-PERS). At initial presentation, when these profiles were obtained without knowledge of subsequent course, there was no significant difference of clinical, echocardiographic, or hemodynamic parameters between these groups ( Figure 1A) , whereas subsequent disease development differed ( Figure 1B ). For comparison with the CVB3 groups, controls (CONT) with normal and adenovirus cardiomyopathy (AdV) patients with severely impaired cardiac function were also examined in the test phase and Figure 2 refers to these 4 groups. In the subsequent validation phase, only CVB3-ELIM and CVB3-PERS patients were investigated ( Figure 1C ).
Deregulated miRs in CVB3 Cardiomyopathy Display Distinct Patterns
No statistically significant differences were observed in protein-coding gene expression between CVB3-ELIM and CVB3-PERS, whereas a set of 16 miRs of 754 measured emerged deregulated (P<0.01) between these groups (Figure 2) . The same miR profiling was also conducted in a control (CONT) and AdV cardiomyopathy group for comparison. If the 4 test cohorts are jointly considered, the miRs deregulated in CVB3-ELIM versus CVB3-PERS may be assigned to different response types as indicated in Figure 2 . Eight miRs show a type I response (Figure 2A) characterized by their strong induction in only one of the test cohorts (CVB3-PERS), whereas in all other groups they are undetectable or low. They include miRs 135b-5p, 155-5p, 190a-5p, 422a, 489-3p, 590-5p, 601, and 1290. All these miRs significantly distinguish CVB3-PERS not only from CVB3-ELIM but also from control and AdV groups. Opposite is the behavior of 8 type II response miRs ( Figure 2B ), which include let-7a-5p and let-7f-5p, miRs 296-5p, 339-5p, 365a-3p, 532-5p, 660-5p, and 520e. They are undetectable in CVB3-PERS and significantly distinguish them from CVB3-ELIM. Seven of these are also expressed in controls and AdV cardiomyopathy hearts, thus distinguishing CVB3-PERS from all other groups. Type II miR-520e differs because it displays high expression in CVB3-ELIM and AdV hearts, but it is undetectable in normal hearts. Figure 3 compares cardiac miR levels in the CVB3-ELIM versus CVB3-PERS validation cohorts ( Figure 1C ) for all miRs with significant predictive potential (Table) . Table I in the Data Supplement.
The cardiac levels of 7 of 8 type II response miRs were closely correlated ( Figure 5 ; Table I in the Data Supplement) . Remarkably, 5 human miRs deregulated in CVB3-PERS versus CVB3-ELIM have no or no close homologues in the murine genome (miRs 489, 601, 1290, 660-5p, and 520e; Figure 4 ), so these do not exist in the currently available murine model of human CVB3 cardiomyopathy. Four of these are only found in primates (Figures I-V in the Data Supplement).
Cardiac miR Profile Predicting the Clinical Course in CVB3 Cardiomyopathy
On the basis of findings from the large-scale miR profiling of the test cohorts, all 16 miRs significantly deregulated (Figure 2) were further investigated in validation cohorts (clinical data in Figure 1C ). The Table shows the univariate ROC analyses of these predictive candidate miRs on their potential to discriminate CVB3-PERS from CVB3-ELIM. All but 2 (miRs 155 and 520e) of the candidates had asymptotic significance P<0.01, and area under the curve was ≥0.85 for 4 of them ( Figure 6 ). Whereas this univariate ROC analysis documents significant discriminative potential even for single miRs, a multivariate ROC analysis derived from the discriminant score after fitting the function from the learning cohort into the validation sample yielded further enhanced area under the curve 0.897±0.071 with a 95% confidence interval 0.758 to 1.000. From the data in Figure 2 and the miR expression correlations in Figure 5 , it is obvious that in the CVB3-PERS patients a regulatory network is altered, so that the use of the entire miR pattern is of course preferable over single miR analysis for the prediction of future clinical course.
Beyond statistical arguments on the predictive potential of single miRs, further considerations convey further interest to type I miRs, including the perspective that these may be novel therapeutic targets. First, they are only induced in CVB3-PERS, making this group of nonrecovering patients clearly distinguishable from all others. Second, unlike the type II miRs, they are low in CONT, indicating that they are not a part of the baseline miR expression pattern of healthy human hearts. Figure 2 ) were further investigated in validation cohorts (Figure 1C) . The univariate ROC analyses of these 16 miRs regarding their potential to discriminate CVB3-PERS from CVB3-ELIM showed (see the Table on the next page) that all but 2 had asymptotic significance P<0.01, and area under the curve (AUC) was ≥0.85 for 4 of them. Figure 6 shows the ROC curves for these 4 miRs separately (A), and the multivariate ROC analysis derived from the discriminant score after fitting the function from the learning cohort into the validation sample which yielded an AUC 0.897±0.071 with a 95% confidence interval (CI) 0.758 to 1.000 (B). May 2015
Expression and Regulation of Type I miRs in Normal Human PBMCs
Most of the miRs in Figures 2 and 3 have not previously been investigated in the context of virus infections or immune diseases. For comparison with the EMB data obtained from these diseased hearts, we therefore determined their expression levels in PBMCs from healthy human donors under basal conditions ( Figure 7A ). We analyzed possible inducers (lipopolysaccharide, PMA-I, interleukin-10, interferon-β) of these type I miRs in PBMCs, but only miR-155 and let-7a showed significant regulation ( Figure 7B ). miR-155 is already known to play important roles in the regulation of the immune response, and the only type I miR to date is linked to and extensively studied in murine viral heart disease. 20 The other type I miRs kept low levels in both resting and stimulated PBMCs.
Type I miR Target Genes and ASO-Based miR Modulation
All type I miRs (Figures 2 and 3) in CVB3-PERS are predicted to affect immune cell functions, and several of them share predicted target genes (CCR7, ROCK1/2, SMAD4, TGFBR2, and TRAF3/4) (Tables II and III in the  Data Supplement) . Upregulation as observed in CVB3-PERS may lead to suppression of multiple chemokines/ receptors (CCL1, CCL20, CCL22, CCR7, and CXCL12) and receptor-ligand systems FAS-FAS ligand (FASLG), TGBF-TGFBR, and TNF-TNFR. Further predicted targets influence antiviral innate immunity including TLR signaling (ITGAV, RIPK20, TOLLIP, TRAF3, and TRAF4), and the antimicrobial activity of monocytes/macrophages including their NO and ROS production and receptor-mediated phagocytosis.
Because the type I miR pattern induced in CVB3-PERS hearts consists of several closely correlated ( Figure 5 ; Table  I in the Data Supplement ) and likely interacting miRs, functional consequences of this pattern are difficult to analyze in its entirety. As a first step toward mechanistic understanding, we therefore investigated the impact of single type I miRs on selected targets in the monocytic THP-1 cell line. Because no inducer of any type I miR (except miR-155) is known to date, which should result in suppression of their targets, we instead used an anti-miR approach using LNA-modified ASOs to suppress single miRs and look for resulting effects on selected target genes. In these experiments, we focused on miRs 135b, 190a, 422a, and 590 because they are not primate specific as several others (Figure 4 ) and therefore can be investigated as possible therapeutic targets in murine myocarditis models in vivo, too.
In THP-1 cells, ASO-mediated targeted ablation of either miR-135b or miR-190b resulted in strongly induced expression of FASLG, whereas FAS remained unchanged (Figure 8 ). This suggests that FASLG and thus the FASLG-FAS system are suppressed in CVB3-PERS hearts with their high miR-135b and miR-190b levels. Because optimal functioning of the FASLG-FAS system is important during the antiviral immune response 21 and regulate disease outcome in murine CVB3 myocarditis, 22 this deregulation may adversely affect a patient's antiviral capacity. Among selected other miR targets, the chemokine CCR7 was induced by ASO-mediated ablation of either miR-135b or miR-422a CCR7 influences priming and distribution of antiviral effector and memory CTL (cytotoxic t lymphocytes) 23 and dendritic cell homing. 24 Given the high levels of both miR-135b and miR-422a in CVB3-PERS hearts, CCR7-mediated signaling in the context of a viral infection should be impaired.
Discussion
Large-Scale Expression Profiling Identifies Simple Predictive miR Pattern
This study had 2 aims. First, identification of clinically relevant novel predictors for the course of a specific viral cardiomyopathies. Second, a more general search for noncoding genomic elements influencing the grossly different antiviral capacity of individuals. FASLG and thus the FASLG-FAS system may be suppressed in CVB3-PERS hearts because of their high miR-135b and miR-190b levels. FASLG-FAS system is important in antiviral immune response 21 and regulates disease outcome in murine CVB3 myocarditis. 22 Among other selected miR targets, chemokine CCR7 was significantly (**P<0.01) induced by ASO-mediated ablation of either miR-135b or miR-422a CCR7 influences priming and distribution of antiviral effector and memory CTL (cytotoxic t lymphocytes) 23 and dendritic cell homing. 24 Because of high levels of both miR-135b and miR-422a in CVB3-PERS hearts, there may be defective CCR7 signaling.
About the first goal, the data show a path from large-scale transcriptome analysis to a simple miR pattern predicting patients at risk for CVB3 persistence and in need of supportive antiviral therapy. Broad-scale screening had to be conducted as a first step because no data were available on predictive mRNA or miR markers for human CVB3 cardiomyopathy. Affymetrix-based analysis revealed no significant differences of protein-coding mRNA levels in CVB3-ELIM versus CVB3-PERS patients. Of course, mRNA expression changes exist between both CVB3 groups and controls, but none of these had predictive value to distinguish CVB3-ELIM from CVB3-PERS patients at initial presentation. In contrast, miR profiling identified deregulated miRs associated with virus persistence in the test cohorts (Figure 2 ), only one of which was previously investigated in any viral disease or CVB3 cardiomyopathy.
The second stage aimed at validation of candidate miRs emerging from this screening phase, in larger patient cohorts ( Figure 3 ). miR data from this validation phase rendered, after correction for multiple testing and multivariate ROC analysis, an miR profile predicting subsequent disease course, which we suggest for clinical use (Table; Figure 6 ). In the future, routine clinical application will have to reveal its overall clinical benefit in clinical practice, which cannot be deduced from our current nonrandomized study. Another concern in this context are comorbidities as confounding factors. The observed differences in miR levels could be associated with some unmeasured difference between the subjects, eg, the virus might be more persistent in people with a particular comorbidity and miRs might be related to that comorbidity. The miRs could then still be used for prediction because this only requires association, but they then might prove poor targets for intervention. As far as possible within the limitations of a nonrandomized study, we could exclude multiple comorbities (cardiovascular, pulmonary, endocrine, and metabolic) as possible confounders.
On this background, one may assume that certain type I response miRs confirmed in the validation phase, for none of which any role in other cardiomyopathies has been described, are of interest as possible new therapeutic targets. Comprehensive miR mapping by next-generation sequencing 25 has not found induction of these miRs (except miR-155) in hypertrophic or dilated cardiomyopathy. [26] [27] [28] In contrast to type II miRs, they are low in control hearts, suggesting that they are not a part of baseline cardiac miR expression in humans. They are normally not even induced in virus-infected hearts, documented by low levels in CVB3-ELIM and also AdV hearts. This argues for a mechanistic role of their induction in CVB3-PERS patients with an apparent defect in their antiviral response. Their induction may adversely affect viral RNA recognition and innate immune response given their predicted influence on multiple relevant genes (Tables II and III in the Data Supplement).
Possible Origins of Differential miR Expression in Patients With High Versus Low Antiviral Capacity
Secondary goal of this study was a search for noncoding transcripts influencing the grossly different antiviral capacity of individuals. Dominance of noncoding miR transcripts with respect to prognostic potential is obvious. However, whether the observed transcript level differences arise at the level of primary miR gene sequences or surrounding regulatory units, from epigenetic modulation [29] [30] [31] of miR-encoding genome regions, or environmental factors, requires additional studies including sequencing and epigenetic mapping of these regions.
Multiple recent evidence suggests a central role of ncRNAs in the genetic programming of complex organisms in health and disease. The observation of a steeply increasing fraction of ncRNAs during evolution, in contrast to an only modest increase in the number of protein-coding genes, is consistent with assumption of a key role of ncRNA species in higher organisms. 1, 2 This assessment is consistent with the current study, which identified major prognosis-related differences not in protein-coding genes, but at the level of miR transcripts.
Viral subversion of the host protein synthesis machinery, to escape immune surveillance, uses multiple mechanism 32 including direct effects of viruses on cellular miRs, and indirect influences and interactions between antiviral interferons and cellular miRs. [33] [34] [35] Virus-encoded miR homologs to eukaryotic miRs have also been described and several virus-specific miRs identified. [34] [35] [36] Whereas to date no data on human CVB3 infections were available, several miRs influenced enterovirus replication in cell and animal models. miR-23b 37 and miR-296-5p (suppressed in CVB3-PERS) inhibit enterovirus 71 replication. 38 CVB3 replication was altered by miR-126, 39 miR-10a*, 40 miR-203, 41 miR-342-5p, 42 miR-141, 43 miR-21, 44 miR-23b, and miR-146b, 45 but none of these miRs were differentially expressed in CVB3-ELIM versus CVB3-PERS. In conjunction with the observation of primate-specificity of several prognostic miRs identified here, this emphasizes the need to include data from humans for improved mechanistic insight into human viral diseases.
Possible Therapeutic Potential of Induced miRs Associated With Low Antiviral Capacity
From a therapeutic perspective, further investigation of those miRs induced in patients with deficient antiviral response is warranted. miR-targeting therapies preferentially use ablative tools, eg, anti-miR-ASOs, which have already been used in clinical studies in multiple fields of medicine, 2,6-8 whereas enhancing tools, eg, miR-overexpression, 46 have not yet fully translated from experimental to clinical work. For this technical reason, type II miRs suppressed in CVB3-PERS seem less suitable for miR-directed therapies when compared with type I miRs. Furthermore, the latter are not a part of the normal human cardiac miRNOME and their ablation therefore less likely to cause side effects.
Direct evidence of therapeutic potential may be obtained by experimental work in appropriate animal models if the target miR is ablated and the effects on disease course are studied. About the new type I miR targets identified here, however, there are certain limitations. Three type I miRs belong to evolutionary recent miR families (Figures I-III in the Data Supplement) and do not exist in earlier species, such as mice, which provide classical models of human CVB3 cardiomyopathy. 28 On top of already known major differences between CVB3 cardiomyopathy in mice and men (eg, inbred mouse strains displaying grossly different disease courses on pure genetic basis versus high genetic heterogeneity of humans), this reveals another limitation of rodent models. The extracted predictive miR profile is a priori human specific, constituting another example of a general issue of investigations into noncoding genomes discussed before, 2 ie, their rapid evolution from earlier species to man. Multiple noncoding elements evolved de novo from rodents as standard disease models, or disappeared on this evolutionary path, eg, lncRNA Braveheart. 47 Nevertheless, mechanistic and therapeutic investigation of type I miRs 135b, 190a, 422a (homologous to murine 378-3p), 590-5p, and 155 is possible both in cell cultures in vitro and murine models in vivo. These miRs exist both in mice and in men (Figure 4) , address important immune-related target genes, and with the exception of miR-155 also have significant predictive potential (Table) and were not yet studied in viral diseases. In other disease contexts, miR-422a was found to be expressed in nonclassical but not in classical monocytes, 48 suggesting an immune-related function. In the circulation of patients with multiple sclerosis, miR-422a was elevated, 49,50 but it was not deregulated in any nonviral cardiomyopathy. [25] [26] [27] [28] In preparation of in vivo studies using ASO-mediated ablation of 4 therapeutic target miRs, pilot experiments in THP-1 cells (Figure 8 ) were conducted. They proved efficient ablative function of the anti-miR ASO sequences used and significant influence of these ASOs on important target genes. Targeted ablation of either miR-135b or miR-190b resulted in strongly induced expression of FASLG, suggesting that FASLG and thus the FASLG-FAS system should be suppressed in CVB3-PERS hearts with their high miR-135b and 190b levels. Among other selected miR targets, the chemokine CCR7 was induced by ablation of either miR-135b or miR-422a, suggesting that CCR7-mediated signaling should be impaired in CVB3-PERS hearts because of the high levels of both miR-135b and miR-422a. These pilot studies in vitro document high capacity of the suspected target miRs to modulate immune responses although only a small fraction of predicted miR targets was investigated. Because of the network character of the closely correlated type I miRs, further dissection of their functions requires in vivo studies in murine myocarditis models under the influence of individual anti-miR ASOs.
From the data in Figures 2 and 3 and the miR expression correlations in Figure 5 , it is obvious that in the CVB3-PERS patients a regulatory network is altered, so that the use of the entire miR pattern is of course preferable over single miR analysis for the prediction of future clinical course. From the clinical perspective, we favor prognostic use of the miR biomarker panel for early intervention with interferon-β in patients prone to virus persistence and clinical deterioration because disease progression in these patients would irreversible if a wait-andsee approach was adopted, whereas treatment side effects would be transient only. We previously showed that during a follow-up of 6 months, there was already significant deterioration of cardiac function if the virus was not eliminated. 51 On the contrary, side effects of interferon-β therapy were always transient. 17, 19 
Limitations
The first stage of this study addressing test cohorts of CVB3 cardiomyopathy patients was a screening process with broad-scale expression profiling of 754 miRs, to identify candidate miRs that might possibly be useful as predictive markers. The second stage aimed at validation of candidate miRs emerging from the screening phase, in larger patient cohorts. After correction for multiple testing and multivariate ROC analysis, an miR profile predicting subsequent disease course was identified. In the future, routine clinical application will have to reveal its overall clinical benefit in clinical practice, which cannot be deduced from our current nonrandomized study.
